Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?
Year: 2020
Type: article
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: European Commission, Royal Australasian College of Physicians, National Research Foundation, South African Medical Research Council, National Research Foundation of Korea, Norges Idrettshøgskole, National Institutes of Health, National Health and Medical Research Council, National Human Genome Research Institute, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases, Fogarty International Center
Awards: G1392126382, NATIENS: A Phase III Randomized Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, Improving Prediction of Drug Action, G4175701887, IMmune-mediated Adverse drug Reactions In African HIV endemic setting (IMARI-SA study), Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors, Developing and evaluating a multimodal antibiotic allergy strategy to improve antimicrobial stewardship in high-risk antibiotic usage populations, G8327274730, G8410702231, Single Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysis, Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study), HIV-associated Tuberculosis Training Program (HATTP), NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
OpenAlex ID: W3092581372